Protara Therapeutics, Inc. - 8-K Filing
Protara Therapeutics reported $177.4 million in cash, cash equivalents, and marketable debt securities as of March 31, 2026, sufficient to fund operations into 2028. The company plans to submit a Biologics License Application for TARA-002 in Lymphatic Malformations by H2 2027 based on STARBORN-1 trial results and expects to initiate the ADVANCED-3 registrational trial for non-muscle invasive bladder cancer in H2 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TARA